- Home
- VRNS vs RLAY Comparison
VRNS vs RLAY Comparison
Compare VRNS & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRNS | RLAY |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | United States | United States |
| Employees | N/A | 192 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.5B |
| IPO Year | 2013 | 2020 |
Fundamental Metrics
Financial Performance| Metric | VRNS | RLAY |
|---|---|---|
| Price | $27.51 | $12.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 21 | 10 |
| Target Price | ★ $42.75 | $19.50 |
| AVG Volume (30 Days) | 2.6M | ★ 3.3M |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.78 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $270,288,000.00 | $15,355,000.00 |
| Revenue This Year | $18.87 | N/A |
| Revenue Next Year | $17.77 | $324.03 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 24.35 | ★ 53.44 |
| 52 Week Low | $19.70 | $2.71 |
| 52 Week High | $63.90 | $17.32 |
Technical Indicators
Market Signals| Indicator | VRNS | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 65.10 | 46.04 |
| Support Level | $20.21 | $6.67 |
| Resistance Level | $28.26 | $17.32 |
| Average True Range (ATR) | 1.34 | 1.03 |
| MACD | 0.40 | -0.50 |
| Stochastic Oscillator | 63.85 | 21.45 |
Price Performance
Historical ComparisonAbout VRNS Varonis Systems Inc.
Varonis Systems is a cybersecurity vendor focused on data privacy and security. The firm is currently undergoing a cloud transition as it weans its on-premises customers over to its cloud products that are delivered as software-as-a-service. The New York-based firm was founded in 2005 and went public in 2014.
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.